Completed
PHASE3
INTERVENTIONAL
NCT06161844
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. OzempicĀ® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
Interventions
Name:
semaglutide injection (HD1916)
Type:
DRUG
Description:
Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: HD1916
Name:
OzempicĀ®
Type:
DRUG
Description:
Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 32 weeks Other Name: Ozempic Injectable Product
Primary Outcomes
Measure:
Change from baseline to week 32 in glycosylated haemoglobin (HbA1c)
TimeFrame:
Week 32
Description:
Trial Information
NCT ID
NCT06161844
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last Updated
December 15, 2025